Description of Business and Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2018

Summary Of Significant Accounting Policies [Line Items]

Schedule of Potentially Dilutive Common Stock Equivalent Securities

The computation of basic and diluted net loss per share for the three months ended March 31, 2018 and 2017 excludes the common stock equivalents of the following potentially dilutive securities because their inclusion would be anti-dilutive:

	Three months ended March 31,
	2018		2017
Vesting of restricted stock units		1,073,036		709,004
Conversion of convertible notes into common stock		14,154,500		814,561
Conversion of convertible related party notes into common    stock		18,743,500		—
Exercise of common stock warrants		31,856		9,740,597
Employee stock purchase plan		111,020		31,459
Exercise of common stock options		7,212,239		5,941,408
		41,326,151		17,237,029

Accounting Standards Update 2014-09

Summary Of Significant Accounting Policies [Line Items]

Schedule of Cumulative Effect of Changes to Condensed Consolidated Balance Sheet for Adoption of New Revenue Guidance

The cumulative effect of the changes made to the condensed consolidated January 1, 2018 balance sheet for the adoption of the new revenue guidance were as follows (in thousands):

	Balance at December 31, 2017			Adjustments due to new revenue guidance				Balance at January 1, 2018
Assets
Accounts receivable, net	$	2,789		$	(111	)	(1)	$	2,678
Deferred costs from commercial product sales		405			(405	)	(2)		—
Liabilities
Accrued expenses and other current liabilities	$	12,449		$	649		(3)	$	13,098
Deferred revenue, net		3,038			(3,038	)	(4)		—
Equity
Accumulated deficit	$	(2,854,898	)	$	1,873		(5)	$	(2,853,025	)

(1) To establish a reserve for product returns

(2) To eliminate deferred costs from commercial product sales previously required by the sell-through method

(3) To record additional accrual for estimated voucher payments related to inventory remaining in the distribution channel at January 1, 2018

(4) To eliminate deferred revenue previously required by the sell-through method

(5) To record the net impact of (1)-(4) in opening accumulated deficit

Schedule of Adoption of New Revenue Guidance Impact on Financial Statements

In accordance with the new revenue guidance, the disclosure of the impact of adoption on the condensed consolidated balance sheet and the condensed consolidated statement of operations and cash flows was as follows (in thousands):

Condensed Consolidated Balance Sheet
	For the three months ended March 31, 2018
	As Reported			Adjustments			Balances without adoption of Topic 606
Assets
Accounts receivable, net	$	1,550		$	130		$	1,680
Deferred costs from commercial product sales		—			361			361
Liabilities
Accrued expenses and other current liabilities	$	15,930		$	(479	)	$	15,451
Deferred revenue, net		—			2,298			2,298
Equity
Accumulated deficit	$	(2,883,410	)	$	(1,328	)	$	(2,884,738	)
Condensed Consolidated Statement of Operations
	For the three months ended March 31, 2018
	As Reported			Adjustments			Balances without adoption of Topic 606
Revenue
Net revenue - commercial product sales	$	3,402		$	589		$	3,991
Expenses
Cost of goods sold	$	4,008		$	44		$	4,052
Net loss		(30,385	)		545			(29,840	)
Condensed Consolidated Statement of Cash    Flows
	For the three months ended March 31, 2018
	As Reported			Adjustments			Balances without adoption of Topic 606
Cash Flows from Operating Activities
Net loss	$	(30,385	)	$	545		$	(29,840	)
Change in:
Accounts receivable, net		1,128			(18	)		1,110
Deferred costs from commercial product sales		—			44			44
Accrued expenses and other current liabilities		2,675			171			2,846
Deferred revenue, net		—			(740	)		(740	)
Cash (used in) provided by operating activities		(21,650	)		2			(21,648	)